ERYTHEMA and Metronidazole

PatientsVille

Find and Compare Side Effects

ERYTHEMA Symptoms and Causes

Fifth disease is a viral infection caused by parvovirus B19. The virus only infects humans; it's not the same parvovirus that dogs and cats can get. Fifth disease mostly affects children. Symptoms can include a low fever, cold symptoms, and a headache. Then you get a red rash on your face. It looks like a "slapped cheek." The rash can spread to the arms, legs, and trunk. Adults who get it might also have joint pain and swelling.

Fifth disease spreads easily, through saliva and mucus. You can get it when an infected person coughs or sneezes. Frequently washing your hands might help prevent getting the virus. Most people become immune to the virus after having it once.

Fifth disease is usually mild and goes away on its own. However, it can be serious if you

ERYTHEMA Clinical Trials and Studies

Treatments might be new drugs or new combinations of drugs, new surgical procedures or devices, or new ways to use existing treatments. The goal of clinical trials is to determine if a new test or treatment works and is safe. Clinical trials can also look at other aspects of care, such as improving the quality of life for people with chronic illnesses. People participate in clinical trials for a variety of reasons. Healthy volunteers say they participate to help others and to contribute to moving science forward. Participants with an illness or disease also participate to help others, but also to possibly receive the newest treatment and to have the additional care and attention from the clinical trial staff.

Comparing of objective sequelae and post-treatment subjective symptoms in three groups of Erythema migrans patients treated with doxycycline: with no accompanying symptoms, with mild and with severe symptoms at the beginning.; Comparison of subjective symptoms between Erythema migrans patients treated with doxycycline and control subjects without a history of Lyme borreliosis.

Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales; Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale; Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA); Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale; Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale; Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale

Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) 5-point Scales; Percentage of Participants with at Least a 2-Grade Decrease from Baseline on SSA Using a 5-Point Scale; Change from Baseline in Rosacea Facial Redness as Measured by Digital Imaging Analysis (DIA); Satisfaction Assessment for Rosacea Facial Redness Using a 5-Point Scale; Symptom Assessment for Rosacea Facial Redness (Skin Sensation Domain Score) Using a 5-Point Scale; Percentage of Participants with at Least a 1-Grade Decrease from Baseline on SSA Using a 5-Point Scale

Percentage of Participants with Treatment-Related Adverse Events; Percentage of Participants with at Least a 2-Grade Decrease from Baseline on Both Clinician Erythema Assessment (CEA) and Subject Satisfaction Assessment (SSA) Using 5-Point Scales

time to relapse of ENL after initial control of symptoms; time, in hours, to control initial episode of ENL relapse from time of starting anti-reactional medication; time, in days, to ENL relapse from date of stopping anti-reactional medication

Clinician Erythema Assessment at 90 days post-treatment compared to baseline; CEA scale at 180 days post-treatment compared to baseline.; CEA scale at 365 days post-treatment compared to baseline.; Patient Self-Assessment (PSA) of Erythema at 90 Days compared to baseline.; Patient Self-Assessment (PSA) of Erythema at 180 Days compared to baseline.; Patient Self-Assessment (PSA) of Erythema at 365 Days compared to baseline.; Dermatology Life Quality Index (DLQI) Assessment at 90 Days post-treatment; Dermatology Life Quality Index (DLQI) Assessment at 180 Days post-treatment; Dermatology Life Quality Index (DLQI) Assessment at 365 Days post-treatment; Colorimeter at 90 Days post-treatment; Colorimeter at 180 Days post-treatment; Colorimeter at 365 Days post-treatment

If you think you may have a medical emergency, call your doctor or 911 immediately.

By accessing this website, you are indicating your acknowledgement and acceptance of these Terms of Use. These Terms of Use are subject to change by WinFirst LLC at any time in its discretion. Your use of WinFirst LLC Site after such changes are implemented constitutes your acknowledgement and acceptance of the changes. Please consult these Terms of Use regularly.
PatientsVille.com does not provide medical advice, diagnosis or treatment. The information contained on PatientsVille.com site has not been scientifically or otherwise verified as to a cause and effect relationship and cannot be used to estimate the incidence of adverse drug reactions or for establishing or changing of patient treatments.